Value of TCT and HR-HPV detection in the screening of cervical cancer.

Objective To evaluate the value of liquid-based thin-layer cytological test (TCT) and high risk human papillomavirus (HR-HPV) detection in the screening of cervica1 cancer. Methods TCT and HC2-HPV-DNA were detected in 687 patients in our hospital from February 2010 to March 2011. Cervical biopsy was taken as the gold standard, ≥CIN Ⅰ (cervical intraepithelial neoplasia) was regarded as positive, the ratio of RLU/CO≥1.0 inHC2-HPV-DAN test as positive, TCT≥ASCUS in TCT test as abnormal. The value of TCT detection, HPV-DNA detection and co-test of TCT and HPV-DNA were analyzed. Results The results for TCT test, HPV-DNA test and co-test of TCT and HPV-DNA were as follows: sensitivity (76.5%, 84.7%, 72.0%), specificity (73.6%, 52.7%, 80.7%), positive predictive value (57.9%, 45.1%, 64.5%), negative predictive value (86.8%, 88.3%, 85.6%), diagnostic accordance rate (74.5%, 62.7%, 77.9%), Kappa value (0.46, 0.30, 0.51). There were significant differences among sensitivity and specificity of TCT test, HC2 test and co-test (P0.05). The co-test had higher positive predictive value than TCT test, HC2 test, but with no statistically significant difference. The diagnostic accordance rate and Kappa value of co-test was the highest, with the best reliability. Conclusion Co-test of TCT and HPV-DNA is more conducive for the early screening of cervical cancer than TCT test and HC2 test.